Curriculum

Lost and Found: Navigating the Maze of Alzheimer Disease and Anti-Amyloid Therapy

Alzheimer disease is evolving—and early action in primary care is more important than ever. This curriculum features four 15-minute microlearning activities and a 1-hour live virtual session to help you detect mild cognitive impairment, apply updated diagnostic criteria, and understand the role of blood-based biomarkers. You'll also explore which patients are most likely to benefit from anti-amyloid therapies. Gain practical tools to confidently navigate the latest in Alzheimer diagnosis and treatment.

Loading... Begin

CME Information

2.00 AMA PRA Category 1 Credits™, 2.00 ABIM MOC or 2.00 AANP, 0.33 AANP Pharm

Release Date: 9/15/2025

Available for credit until 9/15/2026

Topics

Faculty

Learning Objectives

  • Employ strategies that promote the early detection of mild cognitive impairment (MCI) due to Alzheimer disease (AD) into routine primary care practice
  • Discuss recently revised criteria for the diagnosis and staging of AD and their implications for primary care practice, especially regarding the role of blood-based biomarkers
  • Examine the evidence on available anti-amyloid therapies, including which patient populations derive the greatest therapeutic benefit

Courses

2.00 CME/CE CREDITS

5 Courses

Faculty

Andrew E. Budson, MD

Chief of Cognitive Behavioral Neurology, Veterans Affairs Healthcare System, Boston, Massachusetts

Read More
Amy Clouse, MD, FAAFP

Clinical Associate Professor of Family and Community Medicine, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania

Read More

Supported By

This activity is supported by an educational grant from Lilly

Education Partner

Pri-Med Institute